Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone-Reference-Cited by-同舟云学术

Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone

Published:2013-02-26 Issue:4 Volume:28 Page:490-497
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Mov Disord.

Author:

Graham David J.¹,Williams James R.¹,Hsueh Ya-Hui²,Calia Katlyn³,Levenson Mark²,Pinheiro Simone P.¹,MaCurdy Thomas E.,Shih David¹,Worrall Chris⁴,Kelman Jeffrey A.⁴

Affiliation:

1. Office of Epidemiology and Surveillance; Center for Drug Evaluation and Research, Food and Drug Administration; Silver Spring; Maryland; USA

2. Office of Biostatistics; Center for Drug Evaluation and Research, Food and Drug Administration; Silver Spring; Maryland; USA

3. Acumen; LLC; Burlingame; California; USA

4. Centers for Medicare & Medicaid Services; Washington; DC; USA

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Reference28 articles.

1. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease;Najib;Clin Ther,2001

2. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease;Stocchi;The STRIDE-PD study. Ann Neurol,2010

3. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology;Ben-Schlomo;J Neurol Neurosurg Psychiatr,1995

4. Survival time, mortality, and cause of death in elderly patients with Parkinson's disease: a 9-year follow-up;Fall;Mov Disord,2003

5. Parkinsonism in Ontario: comorbidity associated with hospitalization in a large cohort;Guttman;Mov Disord,2004

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Catechol‐O‐methyltransferase inhibition with entacapone: Evidence from controlled clinical trials in Parkinson's disease;European Journal of Neurology;2023-10-15

2. Risk of myocardial infarction in Parkinson's disease: A systematic review and meta‐analysis;European Journal of Neurology;2023-05-21

3. Exercise-mitigated sex-based differences in aging: from genetic alterations to heart performance;American Journal of Physiology-Heart and Circulatory Physiology;2021-02-01

4. Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson’s disease;Expert Opinion on Drug Metabolism & Toxicology;2020-04-27

5. Cardiovascular Adverse Events Reported in Placebo Arm of Randomized Controlled Trials in Parkinson’s Disease;Journal of Parkinson's Disease;2020-04-03